Stockscreener 앱 받기
8.84
2.67%
0.23
시간 외 거래:
8.73
-0.11
-1.24%
전일 마감가:
$8.61
열려 있는:
$8.62
하루 거래량:
42,456
Relative Volume:
0.66
시가총액:
$84.74M
수익:
$789.00K
순이익/손실:
$5.70M
주가수익비율:
10.91
EPS:
0.81
순현금흐름:
$865.00K
1주 성능:
+0.91%
1개월 성능:
+2.43%
6개월 성능:
-55.13%
1년 성능:
-4.33%
1일 변동 폭
$8.4784
$8.86
1주일 범위
$8.27
$9.18
52주 변동 폭
$6.53
$29.98
Seres Therapeutics Inc Stock (MCRB) Company Profile
명칭
Seres Therapeutics Inc
전화
617 945 9626
주소
200 SIDNEY STREET, CAMBRIDGE, MA
Compare MCRB vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
MCRB
Seres Therapeutics Inc
|
8.84 | 82.54M | 789.00K | 5.70M | 865.00K | 0.81 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Seres Therapeutics Inc Stock (MCRB) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-05-08 | 다운그레이드 | Chardan Capital Markets | Buy → Neutral |
| 2024-10-24 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2023-06-26 | 재개 | Oppenheimer | Outperform |
| 2023-04-21 | 개시 | JP Morgan | Neutral |
| 2021-07-23 | 다운그레이드 | Goldman | Neutral → Sell |
| 2021-05-18 | 재개 | Goldman | Neutral |
| 2021-03-05 | 업그레이드 | Chardan Capital Markets | Neutral → Buy |
| 2020-09-18 | 다운그레이드 | Chardan Capital Markets | Buy → Neutral |
| 2020-08-18 | 개시 | Piper Sandler | Overweight |
| 2020-08-11 | 재확인 | H.C. Wainwright | Buy |
| 2020-08-11 | 업그레이드 | Jefferies | Hold → Buy |
| 2019-04-30 | 개시 | Jefferies | Hold |
| 2018-10-22 | 개시 | Chardan Capital Markets | Buy |
| 2017-10-13 | 개시 | Oppenheimer | Outperform |
| 2017-08-04 | 재확인 | H.C. Wainwright | Buy |
| 2017-02-01 | 재확인 | FBR & Co. | Outperform |
| 2016-08-12 | 재확인 | FBR Capital | Outperform |
| 2016-08-01 | 다운그레이드 | BofA/Merrill | Buy → Neutral |
| 2016-08-01 | 재확인 | H.C. Wainwright | Buy |
| 2016-07-29 | 재개 | H.C. Wainwright | Buy |
| 2016-03-30 | 개시 | FBR Capital | Outperform |
| 2016-03-03 | 개시 | Guggenheim | Buy |
| 2016-01-25 | 개시 | H.C. Wainwright | Buy |
| 2015-10-22 | 업그레이드 | BofA/Merrill | Neutral → Buy |
| 2015-07-22 | 개시 | Canaccord Genuity | Buy |
| 2015-07-21 | 개시 | Goldman | Neutral |
| 2015-07-21 | 개시 | Leerink Partners | Outperform |
모두보기
Seres Therapeutics Inc 주식(MCRB)의 최신 뉴스
Aug Catalysts: Is Seres Therapeutics Inc impacted by rising rates2026 AllTime Highs & Safe Entry Trade Signal Reports - baoquankhu1.vn
Seres Therapeutics Stock Price Drops Below 50-Day Average - National Today
Will Seres Therapeutics Inc benefit from green energy policies2026 Chart Watch & High Accuracy Trade Alerts - baoquankhu1.vn
Seres Therapeutics to Present at CARB-X Investor Day - Bitget
Seres brings CARB-X-backed ICU infection therapy to Munich event - Stock Titan
Aug Ideas: Should I invest in Seres Therapeutics Inc before earnings2026 Setups & Low Drawdown Trading Strategies - baoquankhu1.vn
VIX Spike: Does Seres Therapeutics Inc have declining or rising EPSWeekly Stock Analysis & Daily Entry Point Alerts - baoquankhu1.vn
MCRB SEC FilingsSeres Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Market Fear: Can Seres Therapeutics Inc weather a recessionDip Buying & Free High Return Stock Watch Alerts - baoquankhu1.vn
MCRB stock declines as Seres Therapeutics pauses SER-155 phase 2 study and shrinks headcount by 30% - MSN
Market Rankings: Is Seres Therapeutics Inc in a bullish channelTrade Volume Summary & Safe Capital Growth Stock Tips - baoquankhu1.vn
Layoff Tracker: Takeda Restructuring Will Affect Workforce, Could Include Layoffs - BioSpace
Seres Therapeutics (NASDAQ:MCRB) Stock Price Crosses Below 50 Day Moving AverageHere's Why - MarketBeat
Seres Therapeutics cuts 25% of workforce to extend cash runway into Q2 2026 - MSN
Seres Therapeutics (MCRB) price target increased by 31.25% to 21.42 - msn.com
If You Invested $1,000 in Seres Therapeutics Inc (MCRB) - Stock Titan
Seres Therapeutics Sets 2026 Annual Shareholder Meeting Date - The Globe and Mail
MCRB (NASDAQ: MCRB) files Form 144 to resell 8,553 restricted shares - Stock Titan
Kelly Brady Net Worth (2026) - GuruFocus
Seres Therapeutics schedules 2026 annual meeting for June 9 By Investing.com - Investing.com India
Seres Therapeutics schedules 2026 annual meeting for June 9 - Investing.com
Seres Therapeutics sets 2026 annual meeting for June 9; shareholder proposal deadline Mar 26 - TradingView
Seres Therapeutics (MCRB) schedules 2026 meeting, sets proposal deadline - Stock Titan
Seres Therapeutics, Inc. (NASDAQ:MCRB) Short Interest Down 15.4% in February - MarketBeat
MCRB: Canaccord Genuity Maintains Buy Rating with $22 Target | M - GuruFocus
Seres Therapeutics (NASDAQ:MCRB) Receives Buy Rating from Canaccord Genuity Group - MarketBeat
Exit Recap: Is Seres Therapeutics Inc impacted by rising rates2026 Macro Impact & Risk Adjusted Buy and Sell Alerts - baoquankhu1.vn
Seres Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Seres Therapeutics (NASDAQ:MCRB) Releases Earnings Results, Beats Expectations By $0.50 EPS - MarketBeat
Seres Therapeutics 2025 10-K: $0.8M Revenue, net income $5.70M - TradingView
Seres Therapeutics: Q4 Earnings Snapshot - marketscreener.com
Seres Therapeutics Reports 2025 Results, Highlights Refocused Pipeline - TipRanks
Seres (MCRB) Focuses on Advancing Biotherapeutics Portfolio - GuruFocus
Seres Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Seres Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates - Bitget
Seres Therapeutics: Fourth Quarter Earnings Overview - Bitget
Seres Therapeutics (NASDAQ: MCRB) details 2025 profit, cash runway and SER-155 progress - Stock Titan
Seres Therapeutics (MCRB) awards 56,250 stock options to officer - Stock Titan
Seres Therapeutics (MCRB) officer Brady Kelly reports stock holdings - Stock Titan
Seres Therapeutics Inc expected to post a loss of $2.11 a shareEarnings Preview - TradingView
Is Seres Therapeutics Incs ROE strong enough2025 Trading Recap & Free Weekly Watchlist of Top Performers - baoquankhu1.vn
Rally Mode: Should I invest in Seres Therapeutics Inc before earningsGold Moves & High Accuracy Trade Signal Alerts - baoquankhu1.vn
Activity Recap: Should I invest in Seres Therapeutics Inc before earningsWeekly Stock Report & AI Forecasted Stock Moves - baoquankhu1.vn
Aug Action: Does Seres Therapeutics Inc have declining or rising EPSMarket Sentiment Report & Daily Entry Point Alerts - baoquankhu1.vn
Seres Therapeutics Inc (MCRB) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.69%
0.25%
자본화:
|
볼륨(24시간):